Clorox (CLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Werte in diesem Artikel
For the quarter ended December 2024, Clorox (CLX) reported revenue of $1.69 billion, down 15.3% over the same period last year. EPS came in at $1.55, compared to $2.16 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.64 billion, representing a surprise of +3.12%. The company delivered an EPS surprise of +11.51%, with the consensus EPS estimate being $1.39.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Clorox performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic Revenue Growth - Health and Wellness: -13% compared to the -19.8% average estimate based on four analysts. Organic Revenue Growth - International: 6% versus the four-analyst average estimate of -4%. Organic Revenue Growth - Lifestyle: -16% versus the four-analyst average estimate of -26.3%. Organic Revenue Growth - Household: -11% versus -8.5% estimated by four analysts on average. Organic Sales Growth: -9% compared to the -14.1% average estimate based on four analysts. Net Revenue- Health and Wellness: $628 million versus the four-analyst average estimate of $577.80 million. The reported number represents a year-over-year change of -12.8%. Net Revenue- International: $274 million versus the four-analyst average estimate of $259.29 million. The reported number represents a year-over-year change of -11.9%. Net Revenue- Lifestyle: $338 million versus the four-analyst average estimate of $297.10 million. The reported number represents a year-over-year change of -16.1%. Net Revenue- Household: $446 million versus $459.38 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -11.2% change. Income before income taxes- Health and Wellness: $193 million compared to the $176.97 million average estimate based on two analysts. Income before income taxes- Corporate and Other: -$74 million compared to the -$98.17 million average estimate based on two analysts. Income before income taxes- International: $21 million versus $29.33 million estimated by two analysts on average. View all Key Company Metrics for Clorox here>>>Shares of Clorox have returned -2.6% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Clorox Company (CLX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf Clorox
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Clorox
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Clorox Co., The
Analysen zu Clorox Co., The
Datum | Rating | Analyst | |
---|---|---|---|
02.05.2019 | Clorox Hold | Deutsche Bank AG | |
14.12.2017 | Clorox Hold | Deutsche Bank AG | |
09.01.2017 | Clorox Equal Weight | Barclays Capital | |
16.12.2016 | Clorox Outperform | BMO Capital Markets | |
03.11.2016 | Clorox Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
16.12.2016 | Clorox Outperform | BMO Capital Markets | |
06.02.2015 | Clorox Buy | Argus Research Company | |
05.12.2014 | Clorox Buy | Argus Research Company | |
09.07.2012 | Clorox kaufen | Euro am Sonntag | |
16.02.2011 | Clorox outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
02.05.2019 | Clorox Hold | Deutsche Bank AG | |
14.12.2017 | Clorox Hold | Deutsche Bank AG | |
09.01.2017 | Clorox Equal Weight | Barclays Capital | |
03.11.2016 | Clorox Sector Perform | RBC Capital Markets | |
05.05.2016 | Clorox Neutral | B. Riley & Co., LLC |
Datum | Rating | Analyst | |
---|---|---|---|
04.05.2016 | Clorox Sell | UBS AG | |
03.11.2015 | Clorox Sell | UBS AG | |
07.10.2015 | Clorox Underweight | Barclays Capital | |
23.09.2014 | Clorox Sell | B. Riley & Co., LLC | |
03.02.2006 | Update Clorox Co., The: Sell | Oppenheimer |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Clorox Co., The nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen